Cholesterol triple threat: This Is What the Cocktail Looks Like

Beyond the Metro Map | Jane McLelland

Statin. Dipyridamole. Evolocumab. Three drugs, one circuit — and why no single one of them is the answer.

Nothing in this article constitutes medical advice. The science discussed is published, peer-reviewed research. Its application to any individual’s treatment decisions requires a qualified clinician who can assess their specific circumstances.

In 2026, a real-world study was published in JAMA Network Open. It enrolled 478 patients with lung cancer, melanoma, or renal cell carcinoma — all receiving immune checkpoint therapy — and followed them for nine years. Propensity-matched. Multi-centre. The question it was asking was whether the type of lipid-lowering therapy a patient received made any difference to their survival.

It did. Patients who received a PCSK9 inhibitor alongside their checkpoint therapy had a 31% lower risk of dying than those receiving high-intensity statin therapy.

Not statin plus PCSK9 inhibitor. Statin versus PCSK9 inhibitor. And the PCSK9 inhibitor group survived significantly longer.

I want you to hold that number while I explain something. Because the obvious reading of that finding — that PCSK9 inhibitors are better than statins — is not the right reading. The right reading is that they are doing different things. And the reason one outperformed the other in that specific trial context is that the immune evasion mechanisms at play in ICI-treated patients are addressed by the PCSK9 inhibitor and not by the statin.

In a different trial, in a different patient context, the statin might be the dominant effect. In the context of mevalonate pathway compensation, dipyridamole is the dominant effect. Each of these three drugs has a specific job. None of them is sufficient alone. Together, they form a circuit that is mechanistically complete in a way that no individual component achieves.

This is what the cocktail looks like.